Literature DB >> 23632099

Non-classic congenital adrenal hyperplasia.

Selma Feldman Witchel1.   

Abstract

Non-classic or late-onset congenital adrenal hyperplasia (NCAH) due to 21-hydroxylase deficiency is one of the most common autosomal recessive disorders. Reported prevalence is approximately 1 in 1000. Affected individuals typically present due to signs and symptoms of androgen excess. The purpose of this review is to provide current information regarding the pathophysiology, molecular genetics, and management of this common disorder. The treatment of NCAH needs to be directed towards the symptoms. For affected children, goals of treatment include normal linear growth velocity, normal rate of skeletal maturation, "on-time" puberty. For affected adolescent and adult women, goals of treatment include regular menstrual cycles, prevention or progression of hirsutism and acne, and fertility. Treatment needs to be individualized and should not be initiated merely to decrease abnormally elevated hormone concentrations.
Copyright © 2013 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23632099     DOI: 10.1016/j.steroids.2013.04.010

Source DB:  PubMed          Journal:  Steroids        ISSN: 0039-128X            Impact factor:   2.668


  9 in total

Review 1.  Nonclassic congenital adrenal hyperplasia due to 21-hydroxylase deficiency: clinical presentation, diagnosis, treatment, and outcome.

Authors:  Henrik Falhammar; Anna Nordenström
Journal:  Endocrine       Date:  2015-06-17       Impact factor: 3.633

Review 2.  Biochemical and genetic diagnosis of 21-hydroxylase deficiency.

Authors:  Henrik Falhammar; Anna Wedell; Anna Nordenström
Journal:  Endocrine       Date:  2015-09-04       Impact factor: 3.633

3.  Molecular Analysis of 21-Hydroxylase Deficiency Reveals Two Novel Severe Genotypes in Affected Newborns.

Authors:  Paola Concolino; Rosa Maria Paragliola
Journal:  Mol Diagn Ther       Date:  2021-03-12       Impact factor: 4.074

Review 4.  Congenital Adrenal Hyperplasia-Current Insights in Pathophysiology, Diagnostics, and Management.

Authors:  Hedi L Claahsen-van der Grinten; Phyllis W Speiser; S Faisal Ahmed; Wiebke Arlt; Richard J Auchus; Henrik Falhammar; Christa E Flück; Leonardo Guasti; Angela Huebner; Barbara B M Kortmann; Nils Krone; Deborah P Merke; Walter L Miller; Anna Nordenström; Nicole Reisch; David E Sandberg; Nike M M L Stikkelbroeck; Philippe Touraine; Agustini Utari; Stefan A Wudy; Perrin C White
Journal:  Endocr Rev       Date:  2022-01-12       Impact factor: 19.871

5.  Pain and Stress Response during Intravenous Access in Children with Congenital Adrenal Hyperplasia: Effects of EMLA and Nitrous Oxide Treatment.

Authors:  K Ekbom
Journal:  Pain Res Treat       Date:  2017-12-31

6.  A de novo mutation in CYP21A2 gene in a case of in vitro fertilization.

Authors:  Roseane Lopes da Silva-Grecco; Débora de Paula Michelatto; Carolina Rodrigues Lincoln-de-Carvalho; Pamela Pontes Henrique; Heloísa Marcelina da Cunha; Maricilda Palandi-de-Mello
Journal:  Mol Genet Metab Rep       Date:  2015-11-09

Review 7.  Non-Classical Congenital Adrenal Hyperplasia in Childhood.

Authors:  Selim Kurtoğlu; Nihal Hatipoğlu
Journal:  J Clin Res Pediatr Endocrinol       Date:  2016-06-29

8.  CYP21A2 mutations in pediatric patients with congenital adrenal hyperplasia in Costa Rica.

Authors:  Andrés Umaña-Calderón; María José Acuña-Navas; Danny Alvarado; Mildred Jiménez; Fred Cavallo-Aita
Journal:  Mol Genet Metab Rep       Date:  2021-02-09

9.  Nonclassical Congenital Adrenal Hyperplasia and Pregnancy.

Authors:  Neslihan Cuhaci; Cevdet Aydın; Ahmet Yesilyurt; Ferda Alpaslan Pınarlı; Reyhan Ersoy; Bekir Cakir
Journal:  Case Rep Endocrinol       Date:  2015-10-08
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.